Inceptor Bio announces a strategic collaboration with the University of Minnesota to develop a novel iPSC platform for the advancement of next-generation allogeneic cell therapies

MORRISVILLE, North Carolina, June 30, 2022 /PRNewswire/ — Inceptor Bio, a biotechnology company advancing cell therapies for hard-to-treat cancers, today announced a collaboration with University of Minnesota. The goal of this collaboration is to build a novel induced pluripotent stem cell (iPSC) platform that will accelerate Inceptor Bio’s leading next-generation cell therapy platforms. Under the terms of the agreement, Inceptor Bio will receive an exclusive license to the technology developed through this collaboration.

(PRNewsfoto/Inceptor Bio)

Inceptor Bio plans to advance several cell therapy products into clinical studies integrating the iPSC platform into its proprietary K62 platform for CAR-M therapy, which increases the phagocytic abilities of macrophages and supports an anti- tumor M1, as well as its new stimulation co-domain, M83, for CAR-NK therapies.

“iPSC-derived cell therapies have the potential to unlock the next frontier in cell therapies. We are excited to work with Dr. Handsome Webber at University of Minnesota and his team to develop this unique platform,” said Mike NicholsonPh.D., President and COO of Inceptor Bio.

“The team of University of Minnesota is confident that Inceptor Bio is the right partner to build a differentiated iPSC platform to advance novel cell therapies,” said Beau Webber, Ph.D., assistant professor in the Department of Pediatrics, Division of Hematology and ‘oncology. “We are deeply encouraged by Inceptor Bio’s advances in cell therapy, and we look forward to being part of future developments to help cure hard-to-treat cancers.” »

“This partnership is an important step in continuing to execute on our strategy to advance cell therapies to provide a more positive prognosis and quality of life for patients with difficult-to-treat cancers,” said Abe Maingi, Vice President, Business Development at Inceptor Bio. “We are excited to be able to develop and deliver on the promise of iPSC-derived cell therapies.”

About Inceptor Bio

Inceptor Bio is a biotechnology company developing several next-generation cell therapy platforms to deliver cures for underserved and hard-to-treat cancers. Inceptor Bio builds platforms in CAR-T, CAR-M and CAR-NK. Inceptor Bio is headquartered in Morrisville, North Carolina. More information is available at

Media Contact
Abe Maingi
[email protected]



Show original content to download multimedia: next-generation-allogeneic-cellular-therapies-301578265.html

SOURCE Inceptor

Comments are closed.